NL-OMON39021已完成4 期
An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response - STOPIMAPED
Stichting Kinderoncologie Nederland0 个研究点目标入组 6 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 2 至 17（—）
入选标准
- •Pediatric CML patients treated with Imatinib having achieved and maintained complete molecular remission for at least 2 years.
- •Informed consent needs to be signed.
排除标准
- •Non-CML patients, or CML patients with complete cytogenetic reponse but with a moderate molecular response.
研究者
相似试验
进行中（未招募）
不适用
An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response(STOPIMAPED)Chronic Myeloid Leukemia pediatric patients treated with Imatinib having achieved and maintained complete molecular remission for at least 2 years.EUCTR2011-006239-44-NLDutch Childhood Oncology Group60
尚未招募
不适用
An international collaborative study to discontinue Imatinib/Glivec® in pediatric CML patients with sustained complete molecular response (STOPIMAPED).CMLchildrenstop Imatinib/Glivec®complete molecular responseNL-OMON23324SKION/DCOG (Stichting Kinderoncologie Nederland)Leyweg 2992545CJ Den Haag60
已完成
1 期
Pilot study "International collaborative investigation of underlying technology to develop information exchange platform with hairdresser and barber for successful aging in Thailand and Japan"Shop owner and customers in hairdresser/barberJPRN-UMIN000023733Akita University12
招募中
1 期
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastinestandard risk ALK-positive anaplastic large cell lymphoma (ALCL)CTIS2022-501454-11-00GPOH gGmbH132
招募中
3 期
International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of VinblastineDRKS00023541Gesellschaft für pädiatrische Hämatologie und Onkologie (GPOH) gGmbH106